Conversion Labs Announces Endorsement Agreement with Renowned Microbiologist Jack Gilbert
NEW YORK, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (OTCQB:CVLB) (“Conversion Labs” or “Company”), an e-commerce company focused on building and scaling innovative branded consumer products, today announced it has reached an endorsement agreement for iNR Wellness with Jack Gilbert, PhD.
Jack Gilbert has dedicated his research to the microbial interaction between the human immune system and surrounding environment. His research has been featured in leading news outlets like HBO, Vice, Ted Talks and PBS. Currently, he is Faculty Director of the Microbiome Center, a Professor in the Department of Surgery at the University of Chicago Medicine and a Senior Scientist at Marine Biological Laboratory.
“Beta glucan is a widely studied natural ingredient that helps to keep the microbial ecosystem inside our body in equilibrium,” said Dr. Gilbert. “Based on my research and extensive work in this area, the iNR Wellness betaglucan product supports health in a way that makes sense based on our current understanding of gut health and the human immune system.”
Dr. Gilbert participated in a video series (watch here) discussing the microbiome, immune system, and the scientific rational behind beta glucan’s ability to support immune health. He was listed as one of the 50 most influential scientists by Business Insider and has also co-authored “Dirt is Good”, a popular science guide to the microbiome and children’s health.
“Having a renowned opinion leader like Dr. Gilbert involved in the marketing of our INR Wellness product line will make a big difference,” stated Stefan Galluppi, CTO of Conversion Labs. “His willingness to endorse iNR Wellness product line says a lot about the product’s quality, the scientific rational behind the product, and the benefit it can offer to our customers.”
About Conversion Labs
Conversion Labs, Inc. (the "Company") is a technology-driven e-commerce company that builds innovative and proprietary brands. Conversion Labs’ scalable and global advertising technology infrastructure leverages the world’s largest social media, search and e-commerce platforms (Facebook, Google & Amazon) to rapidly and profitably grow our continually expanding product portfolio. To learn more about our corporate strategy, brands or for investor relations please visit www.conversionlabs.com or email us at [email protected].
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, among other thing, statements regarding the offering, the expected gross proceeds, the expected use of proceeds and the expected closing of the offering. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell its products; the expected benefits and efficacy of the Company's products; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC.Source: Conversion Labs, Inc.
Released October 4, 2018